NHS North West London, Southside, 105 Victoria Street, London, SW1E 6QT, UK.
Public Health. 2012 Jan;126(1):57-63. doi: 10.1016/j.puhe.2011.09.009. Epub 2011 Dec 6.
English cancer policy has encouraged primary care trusts (PCTs) to consider their 1-year cancer survival estimates. This study quantifies variation in these estimates across 39 PCTs in the London and South East Coast strategic health authorities, and explores their precision, possible confounding by age and bias due to death certificate only (DCO) registrations.
Retrospective observational study.
One-year relative survival estimates and data on DCO registrations for patients diagnosed with lung, colorectal, breast and prostate cancers between 2002 and 2006 were extracted from the UK Cancer Information Service. Direct age standardization was performed with weightings derived from the standard cancer patient population for Europe. Pearson correlation coefficients between survival estimates and DCO proportions were calculated.
Mean 1-year PCT survival estimates ranged from 6.9 to 19.4 percentage points, and the precision of individual estimates ranged from ±0.9 to ±6.5 percentage points (at 95% confidence level). Age standardization significantly changed the estimates of nine PCTs for breast cancer, five PCTs for lung cancer and three PCTs for colorectal cancer. None of the prostate cancer estimates were affected significantly. DCO proportions were positively associated with lung cancer survival and negatively associated with colorectal and breast cancer survival.
PCT 1-year cancer survival estimates may be informative, but caveats relating to data quality and hence the validity of the estimates means that they require careful investigation before naïve use, as random variation, confounding due to age and bias due to DCO registrations may be significant.
英国癌症政策鼓励初级保健信托机构(PCT)考虑其 1 年癌症生存率预估。本研究定量分析了伦敦和东南海岸战略卫生局的 39 个 PCT 的这些预估值的差异,并探讨了其精度、因年龄导致的混杂因素以及仅基于死亡证明的登记(DCO)可能导致的偏差。
回顾性观察性研究。
从英国癌症信息服务中心提取了 2002 年至 2006 年间诊断为肺癌、结直肠癌、乳腺癌和前列腺癌的患者的 1 年相对生存率预估值和 DCO 登记数据。采用源自欧洲标准癌症患者人群的权重进行直接年龄标准化。计算生存率预估值与 DCO 比例之间的 Pearson 相关系数。
平均 1 年 PCT 生存率预估值范围为 6.9%至 19.4%,个别预估值的精度范围为±0.9%至±6.5%(置信水平为 95%)。乳腺癌的 9 个 PCT、肺癌的 5 个 PCT 和结直肠癌的 3 个 PCT 的年龄标准化估计值发生了显著变化。前列腺癌的估计值没有受到显著影响。DCO 比例与肺癌生存率呈正相关,与结直肠癌和乳腺癌生存率呈负相关。
PCT 的 1 年癌症生存率预估值可能具有信息性,但数据质量相关的注意事项,以及因此对预估值的有效性意味着在盲目使用之前需要进行仔细调查,因为随机变化、因年龄导致的混杂因素以及因 DCO 登记导致的偏差可能是显著的。